Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New registry tracks hidden heart vessel disease

NCT ID NCT05805462

Knowledge-focused Sponsor: CoreAalst BV Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This registry follows over 670 people with chest pain and non-blocked arteries to study how well tiny heart vessels (microcirculation) work. Participants complete questionnaires about their symptoms and are tracked for up to 5 years for heart events like heart attacks or strokes. The goal is to learn if measuring microvascular resistance can predict future problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better identify and manage coronary microvascular disease, potentially reducing heart-related events.
What could go wrong
This is an observational registry, not a treatment trial, so it won't directly test a new therapy. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 671 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutive patients in whom physiological assessment of the microcirculatory function including continuous coronary thermodilution has been performed with a Pressure-wire X within the context of routine clinical care.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years. * Stable patients should have complaints of chest pain suspected of angina pectoris or other symptoms raising the suspicion of IHD and non-obstructive epicardial coronary arteries on invasive coronary angiography (ICA, diameter stenosis of less than 50%) with an FFR \>0.80. * Any other clinical scenario (including in the context of ACS) prompting the physician to assess the function of the coronary microvasculature. Exclusion Criteria: * Unable to provide consent * Unstable hemodynamics * Ongoing chest pain. * Previous CABG * Moderate to severe valvular heart disease * Uncontrolled or recurrent ventricular tachycardia. * Active liver disease or hepatic dysfunction, defined as AST or ALT \> 3 times the ULN. * Comorbidity with life expectancy \<= 2 years. * Severe renal dysfunction, defined as an eGFR \<30 mL/min/1.73 m2. * Subject is currently participating in another investigational drug or device clinical study. * Presence of other anatomic or comorbid conditions, or other medical, social or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary microvascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary microvascular disorder Microvascular Angina

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary microvascular disease

Contacts and locations

Locations

  • Basildon Hospital

    Essex, United Kingdom

  • Bristol Heart Institute

    Bristol, United Kingdom

  • Catharina Hospital

    Eindhoven, Netherlands

  • Clinica La Princesa

    Madrid, Spain

  • Golden Jubilee National Hospital

    Glasgow, United Kingdom

  • Imperial College

    London, United Kingdom

  • Maasstad Ziekenhuis

    Rotterdam, Netherlands

  • OLV Ziekenhuis Aalst

    Aalst, 9300, Belgium

  • Oxford University Hospitals

    Oxford, United Kingdom

  • Radboud Hospital

    Nijmegen, Netherlands

  • Righospitalet

    Copenhagen, Denmark

  • Royal Brompton Hospital

    London, United Kingdom

  • Royal United Hospital Bath NHS Foundation Trust

    Bath, United Kingdom

  • San Carlos Hospital

    Madrid, Spain

  • St. Thomas Hospital, King's College

    London, United Kingdom

  • University Clinical Center of Serbia, University of Belgrade

    Belgrade, Serbia

  • University Hospital Lausanne

    Lausanne, Switzerland

  • University Hospital Puerta del Mar

    Cadiz, Spain

  • University of Mainz

    Mainz, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.